Since it has been proposed that Checkpoint blockade may be unnecessary for the effector function of anti-CTLA-4 antibodies [44] as they induce tumor rejection mainly by selective depletion of Tregs in the tumors rather than blockade of B7-CTLA-4 interaction in lymphoid organs, the partial efficiency of the novel mAbs with respect to Ipilimumab in this blockade activity should not affect their anti-tumor activity, whereas on the contrary it could represent an advantage for reducing the unwanted immune response adverse events. This evidence concerns the gene CTLA4 and neoplasm.